VistaGen Capital Surpluse vs Accounts Payable Analysis

VTGN Stock  USD 2.43  0.05  2.02%   
VistaGen Therapeutics financial indicator trend analysis is much more than just breaking down VistaGen Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether VistaGen Therapeutics is a good investment. Please check the relationship between VistaGen Therapeutics Capital Surpluse and its Accounts Payable accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.

Capital Surpluse vs Accounts Payable

Capital Surpluse vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of VistaGen Therapeutics Capital Surpluse account and Accounts Payable. At this time, the significance of the direction appears to have very week relationship.
The correlation between VistaGen Therapeutics' Capital Surpluse and Accounts Payable is 0.24. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of VistaGen Therapeutics, assuming nothing else is changed. The correlation between historical values of VistaGen Therapeutics' Capital Surpluse and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of VistaGen Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Capital Surpluse i.e., VistaGen Therapeutics' Capital Surpluse and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.24
Relationship DirectionPositive 
Relationship StrengthVery Weak

Capital Surpluse

Accounts Payable

An accounting item on the balance sheet that represents VistaGen Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of VistaGen Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from VistaGen Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into VistaGen Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.As of the 15th of December 2024, Issuance Of Capital Stock is likely to grow to about 135.8 M, while Selling General Administrative is likely to drop about 13.4 M.

VistaGen Therapeutics fundamental ratios Correlations

0.050.99-1.00.180.031.01.00.89-0.1-0.180.181.00.54-0.090.540.690.240.77-0.140.580.02-0.030.80.85-0.41
0.05-0.030.010.120.560.050.050.06-0.28-0.120.770.050.030.890.030.040.050.050.950.350.330.210.070.07-0.14
0.99-0.03-1.00.21-0.030.990.990.89-0.05-0.210.080.990.51-0.190.510.660.170.76-0.220.56-0.06-0.080.790.84-0.43
-1.00.01-1.0-0.190.03-1.0-1.0-0.880.070.19-0.12-1.0-0.530.17-0.53-0.66-0.21-0.750.21-0.570.030.05-0.78-0.830.42
0.180.120.21-0.190.060.180.180.180.09-1.0-0.220.180.09-0.160.20.21-0.490.210.060.35-0.73-0.180.220.21-0.59
0.030.56-0.030.030.060.020.020.3-0.54-0.060.540.020.20.560.330.320.20.340.360.180.390.180.330.28-0.02
1.00.050.99-1.00.180.021.00.88-0.09-0.180.181.00.52-0.090.520.660.230.76-0.140.570.02-0.040.780.84-0.4
1.00.050.99-1.00.180.021.00.88-0.09-0.180.181.00.52-0.090.520.660.230.76-0.140.570.02-0.040.780.84-0.4
0.890.060.89-0.880.180.30.880.88-0.13-0.180.170.880.5-0.090.680.820.210.87-0.190.650.08-0.120.960.97-0.42
-0.1-0.28-0.050.070.09-0.54-0.09-0.09-0.13-0.09-0.46-0.1-0.14-0.26-0.18-0.19-0.4-0.17-0.13-0.04-0.26-0.62-0.14-0.120.27
-0.18-0.12-0.210.19-1.0-0.06-0.18-0.18-0.18-0.090.22-0.18-0.090.16-0.2-0.210.49-0.21-0.06-0.350.730.18-0.22-0.210.59
0.180.770.08-0.12-0.220.540.180.180.17-0.460.220.180.290.870.330.30.670.260.660.270.730.450.20.170.04
1.00.050.99-1.00.180.021.01.00.88-0.1-0.180.180.53-0.090.520.670.230.76-0.140.570.01-0.040.790.84-0.41
0.540.030.51-0.530.090.20.520.520.5-0.14-0.090.290.53-0.020.650.610.430.64-0.20.380.070.220.420.35-0.25
-0.090.89-0.190.17-0.160.56-0.09-0.09-0.09-0.260.160.87-0.09-0.02-0.01-0.020.33-0.030.880.060.610.22-0.05-0.060.22
0.540.030.51-0.530.20.330.520.520.68-0.18-0.20.330.520.65-0.010.960.480.91-0.20.450.150.120.790.71-0.47
0.690.040.66-0.660.210.320.660.660.82-0.19-0.210.30.670.61-0.020.960.440.97-0.20.480.140.060.910.85-0.5
0.240.050.17-0.21-0.490.20.230.230.21-0.40.490.670.230.430.330.480.440.36-0.060.030.760.450.240.20.23
0.770.050.76-0.750.210.340.760.760.87-0.17-0.210.260.760.64-0.030.910.970.36-0.20.490.110.040.910.89-0.5
-0.140.95-0.220.210.060.36-0.14-0.14-0.19-0.13-0.060.66-0.14-0.20.88-0.2-0.2-0.06-0.20.130.280.18-0.17-0.15-0.03
0.580.350.56-0.570.350.180.570.570.65-0.04-0.350.270.570.380.060.450.480.030.490.13-0.09-0.130.60.59-0.45
0.020.33-0.060.03-0.730.390.020.020.08-0.260.730.730.010.070.610.150.140.760.110.28-0.090.340.10.080.5
-0.030.21-0.080.05-0.180.18-0.04-0.04-0.12-0.620.180.45-0.040.220.220.120.060.450.040.18-0.130.34-0.1-0.13-0.28
0.80.070.79-0.780.220.330.780.780.96-0.14-0.220.20.790.42-0.050.790.910.240.91-0.170.60.1-0.10.99-0.49
0.850.070.84-0.830.210.280.840.840.97-0.12-0.210.170.840.35-0.060.710.850.20.89-0.150.590.08-0.130.99-0.47
-0.41-0.14-0.430.42-0.59-0.02-0.4-0.4-0.420.270.590.04-0.41-0.250.22-0.47-0.50.23-0.5-0.03-0.450.5-0.28-0.49-0.47
Click cells to compare fundamentals

VistaGen Therapeutics Account Relationship Matchups

VistaGen Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets5.8M108.3M74.6M21.1M123.7M129.8M
Total Current Liabilities2.8M4.2M5.8M4.6M5.1M3.8M
Total Stockholder Equity(5.7M)92.0M64.7M12.1M114.3M120.0M
Net Debt2.7M(99.4M)(65.1M)(13.9M)(117.0M)(111.2M)
Retained Earnings(201.9M)(219.8M)(267.6M)(326.9M)(356.2M)(374.0M)
Accounts Payable1.8M838.3K2.8M2.5M1.5M1.4M
Cash1.4M103.1M68.1M16.6M119.2M125.1M
Cash And Short Term Investments1.4M103.1M68.1M16.6M119.2M125.1M
Common Stock Total Equity42.8K49.3K180.8K206.7K237.7K249.6K
Common Stock Shares Outstanding1.5M2.9M6.6M7.0M19.4M11.6M
Liabilities And Stockholders Equity5.8M108.3M74.6M21.1M123.7M129.8M
Other Stockholder Equity196.1M311.6M332.3M338.9M470.5M446.9M
Total Liab11.5M16.3M9.9M9.0M9.4M8.3M
Total Current Assets1.6M104.1M71.0M17.5M120.7M126.7M
Common Stock49.3K180.8K206.7K7.3K27K41.8K
Short Long Term Debt Total4.1M3.7M3.0M2.7M2.1M3.1M
Property Plant And Equipment Net3.8M3.6M3.1M2.8M2.3M1.2M
Non Current Assets Total4.2M4.2M3.6M3.6M3.0M3.1M
Non Current Liabilities Total8.7M12.1M4.2M4.4M4.2M4.8M
Property Plant And Equipment Gross3.8M3.6M4.3M2.8M3.5M3.7M
Short Term Debt373.2K367.8K433.3K591K1.1M1.0M
Other Current Liab561.5K1.6M1.3M1.5M1.7M1.1M
Non Currrent Assets Other402.9K576.8K569.1K814.2K726K762.3K
Other Assets402.9K576.8K569.1K814.2K936.3K983.1K
Retained Earnings Total Equity(181.1M)(201.9M)(219.8M)(267.6M)(240.8M)(228.8M)
Other Current Assets2.7K968.6K2.9M869K1.5M1.6M
Deferred Long Term Liab355.1K529K468.2K713.3K820.3K861.3K
Property Plant Equipment3.8M3.6M414.3K2.8M3.2M3.3M
Net Tangible Assets(5.7M)92.0M64.7M12.1M13.9M18.8M
Capital Surpluse192.1M200.1M315.6M336.1M386.5M214.3M
Capital Lease Obligations4.0M3.7M3.0M2.6M2.1M1.9M

Pair Trading with VistaGen Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with VistaGen Stock

  0.88VALN Valneva SE ADRPairCorr
  0.88ERNA Eterna TherapeuticsPairCorr

Moving against VistaGen Stock

  0.74DYAI Dyadic InternationalPairCorr
  0.7BMY Bristol Myers SquibbPairCorr
  0.68ESPR Esperion TherapeuticsPairCorr
  0.46GILD Gilead Sciences Sell-off TrendPairCorr
  0.39DNA Ginkgo Bioworks HoldingsPairCorr
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.74)
Revenue Per Share
0.029
Quarterly Revenue Growth
(0.34)
Return On Assets
(0.39)
Return On Equity
(0.62)
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.